

REFERENCES

- A. El-Halim AZ, Mohsen DA, Elhenfy AA, Abou Gabal MM,** Serum CA-125, soluble CD44 and serum immune complex (CIC) in the staging and follow up of chronic lymphatic malignancies: correlation with prognostic criteria and survival. *The Egyptian Journal of Haematology* 2001; 26 suppl 4:1009-34.
- Abbondanzo SL, Wenig BM:** Non-Hodgkin lymphoma of sinonasal tract: a clinicopathologic and immunophenotypic study of 120 cases. *Cancer* 1995; 75:1281.
- Abid MB, Nasim F, Anwar K, et al.** Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic *Asian Pac J Cancer Prev* 2005; 6(4): 531-4.
- Adami J, Nyren O, Bergstrom R, Ekblom A, McLaughlin JK, Hogman C, et al.** Blood transfusion and non-Hodgkin lymphoma: Lack of association. *Ann Intern Med* 1997; 127:365-71.
- Alici S, Bavbek SE, Kaytan E, et al.** Prognostic factors in localized aggressive non Hodgkin lymphoma. *Am J Clin Oncol* 2003; 26(1):1-5.
- Anderson JR, Armitage JO, Weisenburger DD.** Epidemiology of the non-Hodgkin lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin Lymphoma Classification Project. *Ann Oncol* 1998; 9:717.
- Andreone P, Gramenzi A, Lorenzini S, Biselli M, Cursaro C, Pileri S, et al.** Post transplantation lymphoproliferative disorders. *Arch Intern Med* 2003; 163:1997-2004.
- Ansell SM, Armitage J.** Non-Hodgkin lymphoma: diagnosis and treatment. *Mayo Clin Proc* 2005; 80(8):1087-97.
- Armitage JO, Mauch PM, Harris NL, Bierman P.** Non Hodgkin lymphoma. In: Devita VT, Hellman S, Rosenberg SA (eds). *Cancer Principles and Practice of Oncology*. 6th ed. Lippincott: Williams & wilkins, Philadelphia 2001, P:2256-316.

- Astley SB, Elliott RM.** How strong is the evidence that lycopene supplementation can modify biomarkers of oxidative damage and DNA repair in human lymphocytes? *J Nutr* 2005;135:2071S-3S.
- Aydin F, Yelmaz M, Ozdemir F, et al.** Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin lymphoma. *Am J Clin Oncol* 2002; 25(6):570-2.
- Baar J, Burkes RI, Gospodarowicz M.** Primary non-Hodgkin lymphoma of bone. *Semin Oncol* 1999; 26:270.
- Bairey O, Blickstein D, Stark P, et al.** Serum CA125 as a prognostic factor in non-Hodgkin lymphoma. *Leuk Lymphoma* 2003; 44(10):1733-8.
- Baris D, Zahm SH.** Epidemiology of lymphomas. *Curr Opin Oncol* 2000; 12:383-94.
- Bechter OE, Eisterer W, Dirnhofer S, Pall G et al.** Expression of LFA-1 identifies different prognostic subgroups in patients with advanced follicular center lymphoma FCL. *Leuk Res* 1999; 23(5):483-8.
- Bell DA, Liu Y, Cortopassi GA.** Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers. *J Natl Cancer Inst* 1995; 87:223-4.
- Bellamy WT, Richter L, Frutiger Y, Gregan TM.** Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. *Cancer Res* 1999; 59(3):728-33.
- Bernard W., Paul K., eds.** World Cancer Report. Lyon (France): International Agency for Research on cancer June 2003; 237:241.
- Bertini M, Boccomini C, Calvi R.** The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma. *Recent Results Cancer Res* 2002; 159:149-53.
- Biggar RJ, Horm J, Goedert JJ, Melbye M.** Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. *Am J Epidemiol* 1987; 126:578-86.

- Boulanger E, Gerard J, Gabarre J, Molina JM, Rapp C, Abino JF, et al.** Prognostic factors and outcome of human herpes virus 8-associated primary effusion lymphoma in patients with AIDS. *J Clin Oncol* 2005; 23:4372-80.
- Brogi E, Harris NH.** Lymphomas of the breast: pathology and clinical behavior. *Semin Oncol* 1999; 26:357.
- Bryla CM.** The relationship between stress and the development of breast cancer: A literature review. *Oncol Nurs Forum* 1996; 23:441-8.
- Butel JS, Vilchez RA, Jorgensen JL, Kozinetz CA.** Association between SV40 and non-Hodgkin lymphoma. *Leuk Lymphoma* 2003; 44(Suppl 3): S33-9.
- Caporaso N, Marti GE, Goldin L.** Perspectives on familial chronic lymphocytic leukemia: Genes and the environment. *Semin Hematol* 2004; 41:201-6.
- Carbone A, Gloghini A, Vaccher E, et al.** Kaposi sarcoma associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. *Br J Haematol* 1996; 94:533-43.
- Carbone A.** AIDS-related non-Hodgkin lymphomas: from pathology and molecular pathogenesis to treatment. *Hum pathol* 2002; 33:392-404.
- Carbone PP.** Report of Committee on Hodgkin disease staging. *Cancer Res* 1971; 31:1860.
- Cartwright R, McNally R, Staines A.** The increasing incidence of non-Hodgkin lymphoma (NHL): The possible role of sunlight. *Leuk Lymphoma* 1994; 14:387-94.
- Catassi C, Fabiani E, Corrao G.** Risk of non-Hodgkin lymphoma in coeliac disease. *JAMA* 2002; 287(11):1413-9.
- Cerhan JR, Janney CA, Vachon CM, Habermann TM, Kay NE, potter JD, et al.** Anthropometric characteristics, physical activity, and risk of non-Hodgkin lymphoma subtypes and B-cell chronic lymphocytic leukemia: A prospective study. *Am J Epidemiol* 2002; 156:527-35.

- Cerhan JR, Wallace RB, Folsom AR, potter JD, Munger RG, prineas RJ.** Transfusion history and cancer risk in older women. *Ann Intern Med* 1993; 119:8-15.
- Chang ET, Hjalgrim H, smedby KE, Akerman M, Tani E, Johnsen HE, *et al.*** Body mass index and risk of malignant lymphoma in Scandinavian men and women. *J Natl Cancer Inst* 2005; 97:210-8.
- Chang ET, Smedby KE, Hjalgrim H, *et al.*** Family history of hematopoietic malignancy and risk of lymphoma. *J Nat L Cancer Inst* 2005; 97(19):1466-74.
- Chang ET, Smedby KE, Hjalgrim H, Schollkopf C, Porwit-MacDonald A, Sundstrom C, *et al.*** Medication use and risk of non-Hodgkin lymphoma. *Am J Epidemiol* 2005; 162:965-74.
- Chang ET, Smedby KE, Zhang SM, Hjalgrim H, Melbye M, Ost A, *et al.*** Dietary factors and risk of non-Hodgkin lymphoma in men and women. *Cancer Epidemiol Biomarkers Prev* 2005; 14:512-20.
- Cheng J, Zhou T, Liu C, *et al.*** Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. *Science* 1994; 263:1759-62.
- Chetty R, Hlatwayo N, Muc R, Sabaratnam R, Gatter K.** Plasmablastic lymphoma in HIV+ patients: an expanding spectrum. *Histopathology* 2003; 42:605-9.
- Chiu BC, Weisenburger DD.** An update of the epidemiology of non-Hodgkin lymphoma. *Clin Lymphoma* 2003; 4:161-8.
- Cioc AM, Allen C, Kalmar JR, suster C, Baiocchi R, Nuovo GJ.** Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8. *Am J Surg Pathol* 2004; 28:41-6.
- Clarkson PM, Thompson HS.** Antioxidants: what role do they play in physical activity and health? *Am J Clin Nutr* 2000; 72 (suppl): 637S-46S.
- Connors JM.** Problems in lymphoma management: special sites of presentation. *Oncology* 1998; 12:188.

- Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, *et al*** . Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. *Cancer* 2002; 94:1492-9.
- Dal Maso L, Rezza G, Zambon P, *et al***. Non-Hodgkin lymphoma among young adults with and without AIDS in Italy. *Int J Cancer* 2001; 93:430-35.
- Dave BJ, Nelson M, Pickering DL**. Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization. *Cancer genet cytogenet* 2002; 132(2): 125-32.
- De Sanjose S, Shah KV, Domingo-Domenech E, Engels EA, Fernandez de Sevilla A, Alvaro T, *et al***. Lack of serological evidence for an association between simian virus 40 and lymphoma. *Int J Cancer* 2003; 104:522-4.
- Devesa SS, Fears T**. Non-Hodgkin lymphoma time trends: United States and international data. *Cancer Res* 1992; 52(19 Suppl): 5432s-40s.
- Diaz L, Montero A, Gonzalez-Gross M, *et al***. Influence of alcohol consumption on immunological status: a review. *Eur J Clin Nutr* 2002;56 (Suppl 3): S50-S53.
- Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL**. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. *Am J Surg Pathol* 2005;29:1633-41.
- Dore GJ, Li Y, McDonald A, *et al***. for the National HIV Surveillance Committee. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. *J Acquir Immune Defic Syndr* 2002; 29:388-95.
- Drenou B, Lamy T, Amiot L, *et al***. CD3-CD56+ non-Hodgkin lymphomas with an aggressive behavior related to multidrug resistance. *Blood* 1997; 89:2966-74.
- Dreosti IE**. Zinc and the gene. *Mut Res* 2001;161-7.

- El-Attar I, El-Hattab OH, Nough MA.** Cancer in the Arab World Magnitude of the problem Egyptian Society of Surgical Oncology Conference. UICC 2005; 21-25.
- Elbol kainy MN.** Non-Hodgkin lymphoma. In: Topographic pathology of cancer NCI Cairo University 1998; 157-81.
- Elenitoba-Johnson KS, Jaffe ES.** Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol 1997; 14:35.
- Engels EA, Viscidi RP, Galloway DA, Carter JJ, Cerhan JR, Davis S, *et al.*** Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States. J Natl Cancer Inst 2004; 96:1368-74.
- Estrada DA, Rajodev L, Sparano JA.** Lymphoma, non-Hodgkin. eMedicine Journal 2002; 3(2):1-21.
- Fernberg P, Odenbro A, Bellocco R, *et al.*** Tobacco use, body mass index and the risk of malignant lymphomas – a nation wide cohort study in Sweden. Int J Cancer 2006; 118(9):2298-302.
- Ferreri AJ, Guidoboni M, Ponzone M, *et al.*** Evidence for an association between chlamydia psittaci and ocular adnexal lymphomas. J Nat L Cancer Inst 2004;96:586.
- Filipits M, Jaeger U, Pohl G *et al.*** Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8(3):729-33.
- Finke J, Slanina J, Lange W, *et al.*** Persistence of circulating t(14-18)- positive cell in long term remission after radiation therapy for localized stage follicular lymphoma. J Clin. Oncol 1993; 11:1668.
- Fisher SG, Fisher RI.** The epidemiology of non-Hodgkin lymphoma. Oncogene 2004; 23:6524-34.
- Foon KA, Fisher RI.** Lymphomas. In: Beutler E, Lichtman M, Coller B, Kipps T (eds) William's Hematology. Sixth Edition McGraw-Hill, New York, 2001; P:1237.

- Fowke JH, Chung FL, Jin F, *et al.*** Urinary isothiocyanate levels, brassica, and human breast cancer. *Cancer Res* 2003; 63:3980-6.
- Fritz A, Percy C, Jack A, *et al.*** International classification of diseases for oncology. 3rd edn. Geneva, World Health Organization:2000.
- Gale J, Simmonds PD, Mead GM, *et al.*** Eenteropathy type intestinal T-cell lymphoma: Clinical features and treatment of 31 patients in single center. *J Clin Oncol* 2000; 18:795.
- Gallagher B, Wang Z, Schymura MJ, *et al.*** Cancer incidence in New York State acquired immunodeficiency syndrome patients. *Am J Epidemiol* 2001; 154:544-56.
- Georgescu L, Quinn GC, Schwartzman S, Paget SA.** Lymphoma in patients with rheumatoid arthritis: association with disease state or methotrexate treatment. *Semin Arthritis Rheum* 1997; 26(6):794-804.
- Gharbiah Population-Based Cancer Registry (GPCR).** Middle East Cancer Consortium, Ministry of Health and Population. Cancer profile in Gharbiah and Egypt, 2003.
- Gianni AM, Bregni M, Siena S, *et al.*** High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. *N Engl J Med* 1997; 336:1290-7.
- Glass AG, Karnell LH, Menck HR.** The National Cancer Data Base report on non-Hodgkin lymphoma. *Cancer* 1997; 0:2311.
- Goggins WB, Finkelstein DM, Tsao H.** Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. *Cancer* 2001; 91:874-80.
- Greenlee RT, Murray T, Bolden S, Wingo PA.** Cancer statistics 2000. *CA Cancer J Clin* 2000; 50:7.
- Greer JP, Macon WR, McCurley TL.** Non Hodgkin lymphoma. In: Lee GR, Foerster J, Lukens H, Paraskev F, Geer JP, Rodgers MG (eds.). *Wintrobe's Clinical Haematology*. 10th ed. Williams & Wilkins 1999; Ch. 95:2447-537.
- Greiner TC, Medeiros IJ, Jaffe ES.** Non Hodgkin Lymphoma *Cancer* 1995; 75:370.

- Grulich AE, Vajdic CM.** The epidemiology of non-Hodgkin lymphoma. *Pathology* 2005; 37(6):409-19.
- Grulich AE, Vajdic CM, Kaldor JM, Hughes AM, Krickler A, Fritschi L, *et al.*** Birth order, atopy, and risk of non-Hodgkin lymphoma. *J Natl Cancer Inst* 2005; 97:587-94.
- Grulich AE, Wan X, Law MG, *et al.*** B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin lymphoma in people with AIDS. *AIDS* 2000; 14:133-40.
- Haddadin WJ.** Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization Classification. *Ann Saudi Med* 2005; 25(5):398-403.
- Haion C, Lepage E, Gisselbrecht C *et al.*** Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non-Hodgkin lymphoma: updated results of the prospective study LNH 87-2. *J Clin Oncol* 1997;15:1131-7.
- Hardell L, Eriksson M, Carlberg *et al.*** Use of cellular or cordless telephones and the risk for non-Hodgkin lymphoma. *Int Arch Occup Environ Health* 2005; 78(8):625-32.
- Hardell L, Eriksson M.** A case control study of non-Hodgkin lymphoma and exposure to pesticides. *Cancer* 1999, 85-353.
- Harris NL, Jaffe ES, Stein H *et al.*** A Revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994; 84:1361-92.
- Harris NL, Jaffe ES, Diebold J *et al.*** World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. *J Clin Oncol* 1999; 17:3835.
- Hayes RB, Yin SN, Doseneci M *et al.*** Benzene and dose related incidence of hematologic neoplasms in China, Chinese Academy of preventive Medicine National Cancer Institute Benzene Study Group. *J Natl Cancer Inst* 1997; 89:1065.

- Hengge UR, Ruzicka T, Tyring SK *et al.*** Update on Kaposi sarcoma and other HHV8 associated disease. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. *Lancet Infect Dis* 2002; 2(6):344-52.
- Herrinton IJ, Goldoft M, Schwartz SM, Weiss NS.** The incidence of non-Hodgkin lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants. *Cancer Causes Control* 1996; 7:224.
- Herrinton LJ, Friedman GD.** Cigarette smoking and risk of non-Hodgkin lymphoma subtypes. *Cancer Epidemiol Biomarkers Prev* 1998;7:25-8.
- Herrinton LJ, Goldoft M, Schwartz SM, *et al.*** The incidence of non-Hodgkin lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants. *Cancer Causes Control* 1996;7:224-30.
- Herrinton LJ, Weiss NS, Olshan AF, *et al.*** Multiple myeloma. In: Schottenfeld D, Fraumeni JF Jr, eds. *Cancer epidemiology and prevention*. New York, NY: Oxford University Press, 1996:946-70.
- Hertage P, Devesess.** Quantification of the impact of known risk factor on time treated in non-Hodgkin lymphoma incidence. *Cancer Res* 1992; 52 (Supp): 5566-9.
- Hiorns LR, Nicholls J, Slonae JP.** Peripheral blood involvement in non-Hodgkin lymphoma detected by clonal gene rearrangement as a biological prognostic marker. *Br J Cancer* 1994; 69:347-51.
- Hirose Y, Masaki Y, Oada J *et al.*** Epstein-Barr virus-associated B-cell type non-Hodgkin lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate. *Int J Hematol* 2002; 75(4):412-5.
- Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, *et al.*** Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. *AIDS* 2001; 15:2119-27.
- Holick MF.** Vitamin D: A millenium perspective. *J Cell Biochem* 2003; 88:296-307.
- Holly EA, Lele C.** Non-Hodgkin lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay Area: Allergies, prior medication use, and sexual practices. *J Acquir Immune Defic Syndr Hum Retrovirol* 1997; 15:211-22.

- Huang JZ, Songer WG, Greiner TC *et al.*** The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. *Blood* 2002; 99(7):2285-90.
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.** Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC monographs on the evaluation of carcinogenic risks to humans, vol 67. Lyon: IARC Press, 1996.
- Ichikawa A.** Prognostic and predictive significance of p53 mutation in aggressive B-cell lymphoma. *Int J Hematol* 2000; 71(3); 211-20.
- Iscovich J, paltiel O, Azizi E, *et al.*** Cutaneous lymphoma in Israel, 1985-1993: a population-based incidence study. *Br J Cancer* 1998; 77:170-3.
- Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W.** Intravenous methotrexate for primary central nervous system non-Hodgkin lymphoma in AIDS. *AIDS* 1997; 11:1725-30.
- Jaffe ES, Lee Harris N, Stein H, Vardiman JW, eds:** World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, IARC Press 2001.
- Jaffe ESHN, Stein H, Vardiman JW, Editors.** Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC press; 2001.
- James PT.** Obesity: The worldwide epidemic. *Clin dermatol* 2004; 22:276-80.
- Jensen OM, Paine SL, McMichael AJ, Fabbro-Peray P.** Alcohol. In: Schottenfeld D, Fraumeni JF Jr (eds). *Cancer epidemiology and prevention*. 2nd edn. New York: Oxford University Press; 1996, 290-318.
- Jing H, Ke X, Gao Z, Wang L.** Lymphoma prognostic correlated factors analysis of 88 cases. *Beijing Da Xue Bao* 2003; 35(2):128-31.
- Joske D, Knecht H.** Epstein-Barr virus in lymphomas: A review. *Blood Rev* 1993; 7:215-22.
- Karin E.** Epidemiological and etiology of non Hodgkin lymphoma, *Acta oncology*, 2006; 45:258-271.

- Kato I, Koenig KL, Shore RE, Baptiste MS, Lillquist PP, Frizzera G, *et al.*** Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin lymphoma (NHL) (United States). *Cancer Causes Control* 2002; 13:965-74.
- Khorshed AM, Ragab SH, Khaled HM *et al.*** Potential use of CD44s and sICAM as indicators of disease progression in non-Hodgkin lymphoma. *The Egyptian Journal of Haematology* 2002; 27(3):531-44.
- Khuder SA, Schaub EA, Keller-Byrne JE.** Meta analyses of non-Hodgkin lymphoma and farming. *Scand J Work Environ Health* 1998; 24:255.
- Knowles DM, Pirog EC.** Pathology of AIDS-related lymphomas and other AIDS-defining neoplasms. *Eur J Cancer* 2001; 37:1236-50.
- Kono N, Kanda Y, Yamamoto R, *et al.*** Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin lymphoma: A single center study in Japan. *Leuk lymphoma* 2000; 37(2):151-6.
- Kuppers R, Rajewaky K.** Developmental and functional biology of B-lymphocytes. In: Macuh PM, Armitage JD, Coiffier B, Dalla- Favera R, Harris NL, editors. *Non-Hodgkin lymphoma*. Philadelphia, PA: Lippincott Williams, Wilkins; 2004. P. 771-786.
- Laane E, Tani E, Bjorklund E, *et al.*** Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin lymphoma cytometry. *Clin Cytom* 2005; 64(1):34-42.
- Law G, Parslow R, Mc Kinney P, Cartwright R.** Non-Hodgkin lymphoma and nitrate in drinking water: a study in Yorkshire, United Kingdom. *J Epidemiol Community Health* 1999; 53:383.
- Lecuit M, Abachin E, Martin A, *et al.*** Immunoproliferative small intestinal disease associated with *Campylobacter jejuni*. *N Engl J Med* 2004; 350:239.
- Lens MB, Newton-Bishop JA.** An association between cutaneous melanoma and non-Hodgkin lymphoma. Pooled analysis of published data with a review. *Ann Oncol* 2005; 16:460-5.

- Lernert K, Mobri N, Stein H, Kaiscrling E.** The histopathology of malignant lymphoma. *Br J Haematol* 1975; 31:193.
- Levine AM, Seneviratne L, Espina BM, Wohl AR, Tulpule A, Nathwani BN, *et al.*** Evolving characteristics of AIDS-related lymphoma. *Blood* 2000; 96:4084-90.
- Li Y, Law M, McDonald A, *et al.*** Estimation of risk of cancers before occurrence of acquired immunodeficiency syndrome in persons infected with human immunodeficiency virus. *Am J Epidemiol* 2002; 155:153-58.
- Lim U, Schenk M, Kelemen LE, *et al.*** Dietary determinants of one-carbon metabolism and the risk of non-Hodgkin lymphoma: NCI-SEER Case-Control Study (1998-2000). *Am J Epidemiol* 2005;162:953-64.
- Linch DC, Goldstone AH, Mason DY.** Malignant lymphomas. In: Hoffbrond AV, Lewis SM, Tuddenham EGD (eds). *Postgraduate Haematology*, 4th ed Oxford, Boston, Johannesburg, New Delhi, Singapore: Butterworth Heinemann 1999; 1:479-504.
- Lindelof B, Granath F, Tengvall-Linder M, Ekbom A.** Allergy and cancer. *Allergy* 2005; 60:1116-20.
- Linnet MS, Cartwright RA.** The leukemias. In: Schottenfeld D, Fraumeni JF Jr, eds. *Cancer epidemiology and prevention*. New York, NY: Oxford University Press, 1996:841-92.
- List AF *et al.*** Non-Hodgkin lymphoma of the gastrointestinal Tract: an analysis of clinical and pathologic features affecting outcome. *J Clin Oncol* 1988; 6:1125.
- Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, *et al.*** Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose- adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. *Blood* 2003; 101:4653-9.
- Lori K, Lifang Hou, Susan M. Gapstur, Andrew M. Evens, Dennis D.** Weisenburger, Brain C, Sun exposure and non-Hodgkin lymphoma. A population based, case-control study. *European Journal of Cancer* 2007; 43:2388-2395.

- Lorinez AL.** Cutaneous T-cell lymphoma (mycosis fungoides). *Lancet* 1996; 347:871.
- Lowe SW, Bodis S, Mc Clatchey A, et al.** P53 status and the efficacy of cancer therapy in vivo. *Science* 1994; 266:5185; 807-10.
- Lukes RJ, Craver LF, Hall TC, Rappaport Ruben P.** Report of the nomenclature committee. *Cancer Res* 1996; 26:1311.
- Macintyre EA, Delabesse E .** Molecular approaches to the diagnosis and evaluation of lymphoid malignancies. *Semin Hematol* 1999; 36:373-389.
- Melbye M, Trichopoulos D.** Non-Hodgkin Lymphomas. In: Adami HO, Hunter D, Trichopoulos D, editors. *Textbook of Cancer Epidemiology*, 1st ed. New York: Oxford University Press;2002. p. 535-49.
- Mele A, Pulsoni A, Biance E, et al.** Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multi-center case-control study. *Blood* 2003; 102(3):996-9.
- Mellemkjaer L, Linet MS, Gridley G, et al.** Rheumatoid arthritis and cancer risk. *Eur J Cancer* 1996; 32A:1753.
- Melnyk A, Rodriguez A, Pugh WE, et al.** Evaluation of the Revised European American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin lymphoma. *Blood* 1997; 89:4514-20.
- Merozek K, Bloomfied CD.** Cytogenetics of non-Hodgkin lymphoma and Hodgkin disease. In: Wiernik PH, Canellos GP, Dutcher, JP, Kyle RA (eds). *Neoplastic diseases of the blood*. 3rd ed. New York: Churchill Livingstone 1996; 835-62.
- Mersi EA, Cesarman E, Arvanitakis L, et al.** Human herpes virus 8/Kaposi sarcoma associated herpes virus is a new transmissible virus that infects B cells. *J Exp Med* 1996; 183:2385.
- Mocchegiani E, Giacconi R, Muzzioli M, Cipriano C.** Zinc, infections and immunosenescence. *Mech Aging Dev* 2000; 121:21-35.

- Mokhtar N, Khaled H (eds).** Epidemiology. In: Lymphoma, 1st ed. Cairo-Egypt 2002; (1):1-5.
- Moller MB, Pedersen NT, Christensen BE.** Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. *Am J Hematol* 2003; 74(2):94-8.
- Mori N, Fujii M, Ikeda S, et al.** Constitutive activation of NF-Kappa B in Primary adult T-cell leukemia cells. *Blood* 1999; 93:2360.
- Morra E.** The biological markers of non-Hodgkin lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy. *Int J Biol Markers* 1999; 14(3):149-53.
- Mueller N.** Hodgkin disease. In: schottenfeld D, Fraumeni JF Jr. eds. *Cancer epidemiology and prevention*. New York, NY: Oxford University Press, 1996:893-919.
- Muller AM, Ihorst G, Mertelsmann R, et al.** Epidemiology of non-Hodgkin lymphoma (NHL): trends, geographic distribution and etiology 2005.
- Munksgaard L, Frisch M, Melbye M, et al.** Incidence patterns of lyme disease and cutaneous B-cell non-Hodgkin lymphoma in the United States. *Dermatology* 2000; 201:351.
- Nakatsuka S, Liu A, Dong Z, Nomura S, Takakuwa T, Miyazato H, et al.** Simian virus 40 sequences in malignant lymphomas in Japan. *Cancer Res* 2003; 63:7606-8.
- Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, et al.** Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. *Cancer* 2004; 100:2627-36.
- Nicolaides C, Fountzilas G, Zoumbos N, et al.** Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non Hodgkin Lymphoma Prognostic Index. *Oncology* 1998; 55(5):405-15.
- Niitsu N, Honma Y, Iijima K, et al.** Clinical significance of nm 23-HI proteins expressed on cell surface in non-Hodgkin lymphoma. *Leukemia* 2003; 17(1):196-202.

- Niitsu N, Okamoto M, Nakamine H, *et al.*** simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin lymphoma. *Eur J Haematol* 2002; 68(2):91-100.
- Niitsu N, Sasaki K, Umeda M.** A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin lymphoma. *Leukemia* 1999; 13(9):1434-40.
- NonJongud G, Rao PH, Hegde A.** Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. *Blood* 2002; 99(7):2554-61.
- Nordstrom M, Hardell L, Magnusson A, *et al.*** Occupation and occupational exposure to UV light as risk factors for hairy cell leukaemia evaluated in a case-control study. *Eur J Cancer Prev* 1997; 6:467-72.
- Norval M.** Effects of solar radiation on the human immune system. *J photochem Photobiol B* 2001; 63:28-40.
- Oehm A, Behrmann I, Falk W, *et al.*** Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity web the sFas antigen. *J Biol Chem* 1992; 267:10709-15.
- Okuno SH, Hoyer JD, Ristow K, Witizig TE.** Primary renal non-Hodgkin lymphoma. An usual extranodal site. *Cancer* 1995; 75:2258.
- Oriol A, Ribera JM, Esteve J, Sanz MA, Brunet S, GarciaBoyer R, *et al.*** Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. *Haematologica* 2003; 88:445-53.
- Ostrowski ML.** Malignant lymphoma of bone. *Cancer* 1991; 58:2646.
- Overbaugh J.** HTLV-1 Sweet –talks its way into cells. *Nat Med* 2004; 10:20.
- Parsonnet J, Hansen S, Rodriguez L, *et al.*** *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med* 1994; 330:1267.

- Pasqualucci L, Bereschenko O, Niu H, et al.** Molecular pathogenesis of non-Hodgkin lymphoma: the role of bcl-6. *leuk lymphoma* 2003;44 (Suppl 3): S5-S12.
- Pedersen RK, Pedersen NT.** Primary non-Hodgkin lymphoma of the thyroid gland: a population based study. *Histopathology* 1996; 28:25-32.
- Pereira A, Cervantes F, Montserrat E, et al.** Non-Hodgkin lymphoma of unfavorable histology: a multivariate analysis of factors predicting the response to CHOP. *Hematol Oncol* 1997; 5:203-11.
- Perez CL, Rudoy S.** Anti CD20 monoclonal antibody treatment of human herpes virus-8 associated, body cavity-based lymphoma with unusual phenotype in human immunodeficiency virus-negative patient. *Clinical and Diagnostic Laboratory Immunology* 2001; 8(5):993-6.
- Perez-Encinas M, Villamayor M, Campos A, et al.** Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin lymphoma. *Haematologica* 1998; 83(8):752-4.
- Persson B, Fredrikson M.** Some risk factors for non-Hodgkin lymphoma. *Int J Occup Med Environ Health* 1999; 12:135.
- Pileri SA, Milani M, Fracternali G, et al.** From the REAL classification to the upcoming WHO scheme. A step towards universal categorization of lymphoma entities. *Annals Oncol* 1998; 9:607-612.
- Prasad AS, Kucuk O.** Zinc in cancer prevention. *Cancer Metas Rev* 2002;21:291-5.
- Purdue MP, Bassani DG, Klar NS, Sloan M, Kreiger N, and the Canadian Cancer Registries Epidemiology Research Group.** Dietary factors and risk of non-Hodgkin lymphoma by histologic subtype: a case-control analysis. *Cancer Epidemiol Biomarkers Prev* 2004; 13:1665-76.
- Raphael M, Borisch B, Jaffe ES.** Lymphomas associated with infection by the human immunodeficiency virus (HIV). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. *Pathology and genetics of tumours of haematopoietic and lymphoid tissues*. Lyon: IARC press; 2001. p. 260-3. *World Health Organization Classification of Tumours*; 3.

- Rappaport H.** Tumors of hematopoietic system. In: Atlas of Tumor Pathology. Sec 3, Washington DC. 1966, US Armed Forces Institute of Pathology.
- Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al.** Chemotherapy for human immunodeficiency virus-associated non-Hodgkin lymphoma in combination with highly active antiretroviral therapy. *J Clin Oncol* 2001;19:2171-8.
- Reiche EM, Nunes SO, Morimoto HK.** Stress, depression, the immune system, and cancer. *Lancet Oncol* 2004; 5:617-25.
- Reiter A, Schrappe M, Tiemann M, et al.** Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group trial NHL BFM 90. *Blood* 1999; 94:3294.
- Remes K, Norrback RF, Rosenquist R, et al.** Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. *Br J Cancer* 2000; 82(3):601-7.
- Rickinson AB, Kieff E.** Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM (eds). *Fields virology*. 3rd ed. Lippincott-Raven, Philadelphia PA 1996; 2397-446.
- Ries LAG, Kesary CI, Honkey BF, et al.** SEER cancer statistics review. Bethesda MD 1999.
- Robak T, Robak E, Bartkowiak J, et al.** Low-grade non-Hodgkin lymphoma in patient with systemic lupus erythematosus. *Leuk Lymphoma* 2001; 41(5-6):659-67.
- Rollison DE, Page WF, Crawford H, Gridley G, Wacholder S, Martin J, et al.** Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine. *Am J Epidemiol* 2004; 160:317-24.
- Romagnani S.** Immunologic influences on allergy and the TH1/TH2 balance. *J Allergy Clin Immunol* 2004; 113:395-400.
- Rosado MF, Byrne GE Jr, Ding F, et al.** Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with *Chlamydia psittaci*. *Blood* 2006; 107:467.

- Royer B, cazals-Hatem D, Sibilia J, et al.** Lymphomas in patients with Sjogren's syndrome are marginal-zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. *Blood* 1997; 90:766.
- Salven P, Teerenhovi L, Joensuu H.** A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin lymphoma. *Blood* 1997; 90(8):3167-72.
- Samy A, Ismail K, Hussein H, Seif-El-Dein I, Hablas A, El-Hamzawy H, Ramdan M.** Cancer in Egypt, Gharbiah. Triennial report of 2000-2002 Gharbiah population – based cancer registry 2007; 2:45-49.
- Schollkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Gadeberg O, Roos G, et al.** Cigarette smoking and risk of non-Hodgkin lymphoma-a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 2005; 14:1791-6.
- Schroeder JC, Olshan AF, Baric R, Dent GA, Weinberg CR, Yount B, et al.** A case-control study of tobacco use and other non-occupational risk factors for t(14;18) subtypes of non-Hodgkin lymphoma (United States). *Cancer Causes Control* 2002; 13:159-68.
- Schuler F, Dolken SC, Hirt C, Dolken MT, Mentel R, Gurtler LG, et al.** No evidence for simian virus 40 DNA sequences in malignant non-Hodgkin lymphomas. *Int J Cancer* 2006; 118:498-504.
- Schwaiger M, Wieder H.** Role of PET in lymphoma. *Chang Gung. Med J* 2005; 28(5):315-25.
- Seow A, Lee J, Sng I, et al.** Non-Hodgkin lymphoma in an Asian population: 1968-1992 time trends and ethnic differences in Singapore. *Cancer* 1996; 77:1899.
- Seymour JR, Talpaz M, Cabanillas F, et al.** Serum interleukin-6 levels correlate with prognosis in diffuse large cell lymphoma. *J Clin Oncol* 1995; 13:575-82.
- Shipp MA, Harrington DP, Anderson JR, et al.** The international Non-Hodgkin Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin lymphoma. *N Engl J Med* 1993; 329:987-94.

- Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidoli E, et al.** Characterization of immunologic and virological parameters in HIV-infected patients with primary effusin lymphoma during antitlastic therapy and highly active antiretroviral therapy. *Clin Infect Dis* 2005; 40:1022-7.
- Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, et al.** Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev* 2004; 13:779-86.
- Slymen DJ, Miller TP, Lippman SM, et al.** Immunobiologic factors predictive of clinical outcome in diffuse large cell lymphoma. *J Clin Oncol* 1990; 8:986-93.
- Smedby KE, Hjalgrim H, Melbye M, Torrang A, Rostgaard K, Munksgaard L, et al.** Ultraviolet radiation exposure and risk of malignant lymphomas. *J Natl Cancer Inst* 2005; 97:199-209.
- Smedby KE.** Epidemiology and etiology of non-Hodgkin lymphoma a review *Acta Oncologica* 2006; 45:258-271.
- Sopari ML, Kozak W.** Immunomodulatory effects of Cigarette Smoke. *J Neuroimmunol* 1998; 83:148-56.
- Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, et al.** Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). *J Clin Oncol* 2004; 22:1491-500.
- Steinkellner H, Rabot S, Freywald C, et al.** Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. *Mutat Res* 2001;480-1:285-97.
- Steinmetz KA, Potter JD.** Vegetables, fruit, and cancer prevention: a review. *J Am Diet Assoc* 1996;96:1027-39.
- Stewart M, Malkorska V, Krishnan J, et al.** Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: Successful treatment with rituximab. *Ann Rheum Dis* 2001; 66(9):892-3.

- Strauss DJ.** Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin lymphoma. *Recent Results Cancer Res* 2002; 159:143-8.
- Talamini R, Montella M, Crovatto M, Dal Maso L, Crispo A, Negri E, *et al.*** Non-Hodgkin lymphoma and hepatitis C virus: A case-control study from northern and southern Italy. *Int J Cancer* 2004; 110:380-5.
- Talamini R, Polesel J, Montella M, *et al.*** Food groups and risk of non-Hodgkin lymphoma: a multicenter, case-control study in Italy. *Int J Cancer* 2006; 118(11):287-6.
- Talamini R, Polesel J, Montella M, Maso LD, Crispo A, Spina M, *et al.*** Smoking and non-Hodgkin lymphoma: Case-control study in Italy. *Int J Cancer* 2005; 115:606-10.
- Tavani A, Negri E, Franceschi S, Talamini R, Serraino D, La Vecchia C.** Hair dye use and risk of lymphoid neoplasms and soft tissue sarcomas. *Int J Cancer* 2005; 113:629-31.
- The Non-Hodgkin Lymphoma Classification Project.** A clinical evaluation of the International Lymphoma Study Group Classification of non Hodgkin Lymphoma. *Blood* 1998; 89:3909-3918.
- Thomas JO.** Acquired immunodeficiency syndrome associated cancer in Sub-Saharan Africa. *Semin Oncol* 2001; 28:198-206.
- Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, *et al.*** Multi drug resistance (MDR-1) expression in AIDS- related lymphomas. *Leuk Res* 2002; 26:121-7.
- Turner J, Hughes AM, Kricker A, Milliken S, Grulich A, Kaldor J and Armstrong B.** Use of WHO lymphoma classification in a population-based epidemiological study, *Annals of oncology* 2004; 15:631-637.
- Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM .** Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. *Arthritis Rheum* 1996; 39(5):767-72.

- Vilchez RA, Madden CR, Kozienetz CA, Halvorson SJ, White ZS, Jorgensen JL, et al.** Association between simian virus 40 and non-Hodgkin lymphoma. *Lancet* 2002; 359:817-23.
- Vitolo U, Bertini M, Brusamolino E, et al.** MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. *J Clin Oncol* 1992; 10:219-27.
- Vitolo U, Botto B, Capello D et al.** Point mutations of BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. *Leukemia* 2002; 16(2)268-75.
- Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, et al.** Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. *Cancer* 2003; 98:1196-205.
- Warzocha K, Salles G, Bienvenu J, et al.** Tumor necrosis factor ligand receptor system can predict treatment outcome in lymphoma patients *J Clin Oncol* 1997; 15:499-508.
- Wieder T, Prokop A, Bagci B, et al.** Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. *Leukemia* 2001; 15:1735-42.
- Willett EV, Smith AG, Dovey GJ, Morgan GJ, Parker J, Roman E.** Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma. *Cancer Causes Control* 2004; 15:771-80.
- Yan Y, Chan WC, Weisenburger DD, et al.** Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. *J Clin Oncol* 1995; 13:1336-42.
- Ye BH.** BCL-6 in the pathogenesis of non-Hodgkin lymphoma. *Cancer Invest* 2000; 18:356-65.

- Zettl A, Lee SS, Rudiger T, et al.** Epstein-Barr virus associated B-cell lymphoma, proliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. *Am J Clin Pathol* 2002; 117(3):368-79.
- Zhang S, Hunter DJ, Rosner BA, Colditz GA, Fuchs CS, Speizer FE, et al.** Dietary fat and protein in relation to risk of non-Hodgkin lymphoma among women. *J Natl Cancer Inst* 1999;91:1751-8.
- Zhang SM, Hunter DJ, Rosner BA, et al.** Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin lymphoma among women. *Cancer Epidemiol Biomarkers Prev* 2000; 9:477-85.
- Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, et al.** Hair-coloring product use and risk of non-Hodgkin lymphoma: A population-based case-control study in Connecticut. *Am J Epidemiol* 2004; 159:148-54.
- Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang B, et al.** Menstrual and reproductive factors and risk of non-Hodgkin lymphoma among Connecticut women. *Am J Epidemiol* 2004; 160:766-73.
- Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al.** Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. *Cancer Causes Control* 2004; 15:419-28.
- Zheng T, Holford TR, Leaderer B, Zhang Y, Zahm SH, Flynn S, et al.** Diet and nutrient intakes and risk of non-Hodgkin lymphoma in Connecticut women. *Am J Epidemiol* 2004; 159:454-66.
- Zhu K, Levine RS, Gu Y, et al.** Non Hodgkin lymphoma and family history of malignant tumors in a case control study (United States). *Cancer Causes Control* 1998; 9:77.
- Zucca E, Bertoni F, Roggero E, et al.** Molecular analysis of the progression from *Helicobacter Pylori*-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach *N Engl J Med* 1998;338:804.
- Zuckerman E, Zuckerman T, Levine AM, et al.** Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. *Ann Intern Med* 1997; 127:423.